Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc.

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

Bristol-Myers Squibb Company is commencing , through its wholly owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics, Inc. (NASDAQ: ZGEN). Bristol-Myers Squibb announced on Tuesday, September 7, 2010 its intent to acquire ZymoGenetics.

Upon the successful closing of the tender offer, shareholders of ZymoGenetics will receive $9.75 in cash for each share of ZymoGenetics common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, ZymoGenetics will become a subsidiary of Bristol-Myers Squibb.

 

Latest stories

Related stories

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back